Santin, Alessandro D.

Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer

Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., et al. (2019) · New England Journal of Medicine

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 874

FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients

Tassi, R. A., Todeschini, P., Siegel, E. R., Calza, S., Cappella, P., Ardighieri, L., Cadei, M., Bugatti, M., Romani, C., Bandiera, E., et al. (2017) · Journal of Experimental & Clinical Cancer Research

Ovarian cancer diagnosis and treatmentEndometrial and Cervical Cancer Treatments

Cited by 67

Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).

Banerjee, S. N., Ring, K. L., Van Nieuwenhuysen, E., Fabbro, M., Aghajanian, C., Oaknin, A., Colombo, N., Santin, A., Clamp, A. R., Moore, K. N., et al. (2023) · Journal of Clinical Oncology

Ovarian cancer diagnosis and treatmentOvarian function and disorders

Cited by 38

Role of the terminal repeat GAGC trimer, the major Rep78 binding site, in adeno‐associated virus DNA replication

Bishop, B. M., Santin, A. D., Quirk, J. G., & Hermonat, P. L. (1996) · FEBS Letters

Virus-based gene therapy researchRNA Interference and Gene Delivery

Cited by 11